skip to Main Content
Some Monoclonal Therapy COVID-19 Treatments Paused By Caldwell Health Officials

Some Monoclonal Therapy COVID-19 Treatments Paused By Caldwell Health Officials

The Caldwell County Health Department announced that allocations of some monoclonal therapy treatments have been paused. According to a news release issued last week by the department, The Assistant Secretary for Preparedness and Response (ASPR) paused allocation of some monoclonal therapies used to treat patients who test positive for COVID-19.

This type of therapy relies on monoclonal antibodies. These are antibodies that are similar to the ones your body would naturally make in response to infection. However, monoclonal antibodies are mass-produced in a laboratory and are designed to recognize a specific component of this virus, the spike protein on its outer shell. By targeting the spike protein, these specific antibodies interfere with the ability of the virus to attach and gain entry into human cells. They give the immune system a leg up until it can mount its own response.

Allocations of bamlanivimab and etesevimab together, etesevimab alone, and REGEN-COV have been paused pending updated data from the CDC. According to the FDA and ASPR, these monoclonal antibodies may not work against current circulating COVID variants, including Omicron, which continues to increase across the U.S.

Based on these federal changes and recommendations, the Caldwell County Health Department and EMS will provide monoclonal treatments on a limited basis. Caldwell County Health Director Anna Martin said the department will continue to monitor federal and state guidance and adapt their delivery of monoclonal treatment accordingly.